Ipsen S.A. acquires private, life sciences company OctreoPharm Sciences, for EUR 50 mln in upfront and downstream payments
Downstream payments will be contingent upon clinical and regulatory milestones. The acquisition includes an agreement with Eckert and Ziegler, one of OctreoPharm's shareholders, to provide contract manufacturing services for the radio-labeling of the therapeutic compound.